The Functional Cancer Genomics group directed by Prof. J.P. Theurillat at the Institute of Oncology Research in Bellinzona, Switzerland (http://www.ior.iosi.ch) is seeking a Postdoctoral fellow.
The successful candidate will work as part of an international team that is dedicated to understanding how new driver alterations culled from cancer genome characterization studies promote tumorigenesis, and how gathered insights can be exploited to develop precision medicines. The position offers excellent scientific opportunities in a highly stimulating and interdisciplinary environment involving close interactions between medical and basic scientists. Investigations range from projects related to:
- Functional characterization of new prostate cancer drivers implicated in chromatin remodeling and protein ubiquitylation
- Engineering of small molecules against key targets of lethal prostate cancer
- Generation of mouse models of prostate cancer progression
- Determined to solve important and challenging questions in biology/medicine
- Ph.D or M.D./Ph.D. (already obtained or soon-to-be)
- At least one first author publication
- Strong background in cancer cell biology (ubiquitin & chromatin biology)
- Experience in CRISPR-Cas9 editing of point mutations in human cell lines
The position is located at the Institute of Oncology Research, a leading institution in basic and translational cancer research in Southern Switzerland with state-of-the-art core facilities and competitive salaries. The highly collaborative lab has ongoing projects with groups at Harvard, MIT and ETHZ, among others.
“For inquiry regarding this job and submission of applications including two references please contact
Prof. Jean-Philippe Theurillat via email: firstname.lastname@example.org.
Starting date Fall to Winter 2017
Selected recent publications:
-Janouskova H, et al. Opposing effects of cancer type-specific SPOP mutations on BET protein degradation and sensitivity to BET inhibitors. Accepted for publication Nat Med 2017.
-Groner A, et al. TRIM24 is an oncogenic transcriptional activator in prostate cancer. Cancer Cell 2016 PMID: 27238081
-Theurillat JP, et al. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. Science 2014 PMID: 25278611
-Whittaker SR, et al. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov 2013 PMID: 23288408
-Barbieri CE1, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 2012 PMID: 22610119
-Theurillat JP, et al. URI is an oncogene amplified in ovarian cancer cells and is required for their survival. Cancer Cell. 2011 PMID: 21397856